Cargando…

Agitation in Dementia: Relation to Core Cerebrospinal Fluid Biomarker Levels

BACKGROUND: The objective of this study was to examine the associations of agitation with the cerebrospinal fluid dementia biomarkers total-tau (T-tau), phosphorylated-tau (P-tau) and Aβ(1-42). METHODS: One hundred patients (mean age ± SD, 78.6 ± 7.5 years) with dementia and neuropsychiatric symptom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bloniecki, Victor, Aarsland, Dag, Cummings, Jeffrey, Blennow, Kaj, Freund-Levi, Yvonne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2014
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176467/ https://www.ncbi.nlm.nih.gov/pubmed/25298777 http://dx.doi.org/10.1159/000363500

Ejemplares similares

Are neuropsychiatric symptoms in dementia linked to CSF biomarkers of synaptic and axonal degeneration?
por: Bloniecki, Victor, et al.
Publicado: (2020)

Cerebrospinal Fluid Levels of sAPPα and sAPPβ in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates
por: Mulugeta, Ezra, et al.
Publicado: (2011)

Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: Their Role in Clinical Chemistry
por: Blennow, Kaj, et al.
Publicado: (2000)

Normalisation of cerebrospinal fluid biomarkers parallels improvement of neurological symptoms following HAART in HIV dementia – case report
por: Andersson, Lars-Magnus, et al.
Publicado: (2006)

Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease
por: Hall, Sara, et al.
Publicado: (2016)

Extracellular fluid, cerebrospinal fluid and plasma biomarkers of axonal and neuronal injury following intracerebral hemorrhage
por: Tobieson, Lovisa, et al.
Publicado: (2021)

Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression
por: Siafarikas, Nikias, et al.
Publicado: (2021)

Author Correction: Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression
por: Siafarikas, Nikias, et al.
Publicado: (2022)

Cerebrospinal fluid neurogranin and YKL‐40 as biomarkers of Alzheimer's disease
por: Janelidze, Shorena, et al.
Publicado: (2015)

Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia
por: Llorens, Franc, et al.
Publicado: (2020)

Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples
por: Skillbäck, Tobias, et al.
Publicado: (2013)

Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: an elusive quest
por: Foiani, Martha S, et al.
Publicado: (2019)

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
por: Gisslén, Magnus, et al.
Publicado: (2009)

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2014)

Cognitive impairment without altered levels of cerebrospinal fluid biomarkers in patients with encephalitis caused by varicella-zoster virus: a pilot study
por: Eckerström, Marie, et al.
Publicado: (2020)

Cerebrospinal Fluid Biomarkers for Dementia with Lewy Bodies
por: Mukaetova-Ladinska, Elizabeta B., et al.
Publicado: (2010)

Cerebrospinal Fluid Analysis Should Be Considered in Patients with Cognitive Problems
por: Zetterberg, Henrik, et al.
Publicado: (2010)

Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease
por: Nilsson, Johanna, et al.
Publicado: (2021)

APLP1 as a cerebrospinal fluid biomarker for γ-secretase modulator treatment
por: Sjödin, Simon, et al.
Publicado: (2015)

Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington’s disease
por: Lowe, Alexander J., et al.
Publicado: (2020)

Differential impairment of cerebrospinal fluid synaptic biomarkers in the genetic forms of frontotemporal dementia
por: Sogorb-Esteve, Aitana, et al.
Publicado: (2022)

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

Interactions between apolipoprotein E, sex, and amyloid-beta on cerebrospinal fluid p-tau levels in the European prevention of Alzheimer's dementia longitudinal cohort study (EPAD LCS)
por: Saunders, Tyler S., et al.
Publicado: (2022)

Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease
por: Hölttä, Mikko, et al.
Publicado: (2013)

Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles
por: Delaby, Constance, et al.
Publicado: (2022)

Validation of a prefractionation method followed by two-dimensional electrophoresis – Applied to cerebrospinal fluid proteins from frontotemporal dementia patients
por: Hansson, Sara Folkesson, et al.
Publicado: (2004)

Stable cerebrospinal fluid neurogranin and β-site amyloid precursor protein cleaving enzyme 1 levels differentiate predementia Alzheimer’s disease patients
por: Kirsebom, Bjørn Eivind, et al.
Publicado: (2022)

Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study
por: Stomrud, Erik, et al.
Publicado: (2015)

Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory
por: Ljubenkov, Peter A., et al.
Publicado: (2018)

Classical Cerebrospinal Fluid Biomarkers in Dementia with Lewy Bodies
por: Foska, Aikaterini, et al.
Publicado: (2022)

Neuronal and Glia-Related Biomarkers in Cerebrospinal Fluid of Patients with Acute Ischemic Stroke
por: Hjalmarsson, Clara, et al.
Publicado: (2014)

Cerebrospinal fluid biomarkers of axonal and synaptic degeneration in a population-based sample
por: Arvidsson Rådestig, Maya, et al.
Publicado: (2023)

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
por: Cicognola, Claudia, et al.
Publicado: (2021)

Peptidome Analysis of Cerebrospinal Fluid by LC-MALDI MS
por: Hölttä, Mikko, et al.
Publicado: (2012)

Molecular forms of neurogranin in cerebrospinal fluid
por: Nazir, Faisal Hayat, et al.
Publicado: (2020)

Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease
por: Babić, Mirjana, et al.
Publicado: (2014)

High tau levels in cerebrospinal fluid predict nursing home placement and rapid progression in Alzheimer’s disease
por: Degerman Gunnarsson, Malin, et al.
Publicado: (2016)

Cognitive Performance and Cerebrospinal Fluid Biomarkers of Neurodegeneration: A Study of Patients with Bipolar Disorder and Healthy Controls
por: Rolstad, Sindre, et al.
Publicado: (2015)

Cerebrospinal fluid sCD27 levels indicate active T cell-mediated inflammation in premanifest Huntington's disease
por: Niemelä, Valter, et al.
Publicado: (2018)

Increased Cerebrospinal Fluid Levels of Ubiquitin Carboxyl-Terminal Hydrolase L1 in Patients with Alzheimer's Disease
por: Öhrfelt, Annika, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_m88age573a48j61f8rmoaqoude